首页> 外文OA文献 >The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years
【2h】

The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years

机译:踝关节损伤管理(aIm)试验:一项实用,多中心,等效随机对照试验和经济评估比较紧密接触铸造与开放手术复位和内固定治疗60岁以上患者的不稳定踝关节骨折

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: ududClose contact casting (CCC) may offer an alternative to open reduction and internal fixation (ORIF) surgery for unstable ankle fractures in older adults.ududObjectives: ududWe aimed to (1) determine if CCC for unstable ankle fractures in adults aged over 60 years resulted in equivalent clinical outcome compared with ORIF, (2) estimate cost-effectiveness to the NHS and society and (3) explore participant experiences.ududDesign: ududA pragmatic, multicentre, equivalence randomised controlled trial incorporating health economic evaluation and qualitative study.ududSetting: ududTrauma and orthopaedic departments of 24 NHS hospitals.ududParticipants: ududAdults aged over 60 years with unstable ankle fracture. Those with serious limb or concomitant disease or substantial cognitive impairment were excluded.ududInterventions: ududCCC was conducted under anaesthetic in theatre by surgeons who attended training. ORIF was as per local practice. Participants were randomised in 1 : 1 allocation via remote telephone randomisation. Sequence generation was by random block size, with stratification by centre and fracture pattern.ududMain outcome measures: ududFollow-up was conducted at 6 weeks and, by blinded outcome assessors, at 6 months after randomisation. The primary outcome was the Olerud–Molander Ankle Score (OMAS), a patient-reported assessment of ankle function, at 6 months. Secondary outcomes were quality of life (as measured by the European Quality of Life 5-Dimensions, Short Form questionnaire-12 items), pain, ankle range of motion and mobility (as measured by the timed up and go test), patient satisfaction and radiological measures. In accordance with equivalence trial US Food and Drug Administration guidance, primary analysis was per protocol.ududResults: ududWe recruited 620 participants, 95 from the pilot and 525 from the multicentre phase, between June 2010 and November 2013. The majority of participants, 579 out of 620 (93%), received the allocated treatment; 52 out of 275 (19%) who received CCC later converted to ORIF because of loss of fracture reduction. CCC resulted in equivalent ankle function compared with ORIF at 6 months {OMAS 64.5 points [standard deviation (SD) 22.4 points] vs. OMAS 66.0 points (SD 21.1 points); mean difference –0.65 points, 95% confidence interval (CI) –3.98 to 2.68 points; standardised effect size –0.04, 95% CI –0.23 to 0.15}. There were no differences in quality of life, ankle motion, pain, mobility and patient satisfaction. Infection and/or wound problems were more common with ORIF [29/298 (10%) vs. 4/275 (1%)], as were additional operating theatre procedures [17/298 (6%) vs. 3/275 (1%)]. Malunion was more common with CCC [38/249 (15%) vs. 8/274 (3%); p  0.001]. Malleolar non-union was lower in the ORIF group [lateral: 0/274 (0%) vs. 8/248 (3%); p = 0.002; medial: 3/274 (1%) vs. 18/248 (7%); p  0.001]. During the trial, CCC showed modest mean cost savings [NHS mean difference –£644 (95% CI –£1390 to £76); society mean difference –£683 (95% CI –£1851 to £536)]. Estimates showed some imprecision. Incremental quality-adjusted life-years following CCC were no different from ORIF. Over common willingness-to-pay thresholds, the probability that CCC was cost-effective was very high (> 95% from NHS perspective and 85% from societal perspective). Experiences of treatments were similar; both groups endured the impact of fracture, uncertainty regarding future function and the need for further interventions.ududLimitations: ududAssessors at 6 weeks were necessarily not blinded. The learning-effect analysis was inconclusive because of limited CCC applications per surgeon.ududConclusions: ududCCC provides a clinically equivalent outcome to ORIF at reduced cost to the NHS and to society at 6 months.ududFuture work: ududLonger-term follow-up of trial participants is under way to address concerns over potential later complications or additional procedures and their potential to impact on ankle function. Further study of the patient factors, radiological fracture patterns and outcomes, treatment responses and prognosis would also contribute to understanding the treatment pathway.ududTrial registration: ududCurrent Controlled Trials ISRCTN04180738.ududFunding: ududThe National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 75. See the NIHR Journals Library website for further project information. This report was developed in association with the National Institute for Health Research Oxford Biomedical Research Unit funding scheme. The pilot phase was funded by the AO Research Foundation.
机译:背景: ud ud近距离接触铸造(CCC)可以为老年人的不稳定踝关节骨折提供切开复位内固定(ORIF)手术的替代方法。 ud ud目标: ud ud我们旨在(1)确定CCC是否与ORIF相比,对于60岁以上成年人的不稳定踝部骨折,其临床结果相当,(2)估算了NHS和社会的成本效益,(3)探索了参与者的经验。 ud ud设计: ud ud务实,多中心,等价的随机对照试验,其中包括健康经济评估和定性研究。 ud ud设置: ud ud24个NHS医院的创伤和骨科。 ud ud参与者: ud ud 60岁以上的成人,踝关节不稳定骨折。 ud ud干预措施: ud udCCC由参加培训的外科医生在剧院麻醉下进行。 ORIF按照当地惯例进行。通过远程电话随机分配参加者以1:1分配。主要结果测量: ud ud随访在第6周进行,随访结果由盲人评估者在随机化后第6个月进行。主要结局是6个月时患者报告的踝关节功能评估Olerud-Molander踝关节评分(OMAS)。次要结果是生活质量(根据《欧洲生活质量5维标准》(简短表格)对12个项目进行测量),疼痛,踝关节活动度和活动性范围(通过定时上门测试),患者满意度和放射学措施。根据美国食品药品监督管理局的等效试验指南,按照协议进行初步分析。 ud ud结果: ud ud我们在2010年6月至2013年11月期间招募了620名参与者,其中95名来自试点,525名来自多中心阶段。 620名参与者中的579名(93%)中的大多数接受了分配的治疗; 275例接受CCC治疗的患者中有52例(19%)由于骨折复位失败而转为ORIF。在6个月时,CCC与ORIF相比具有相同的踝关节功能(OMAS 64.5点[标准差(SD)22.4点]与OMAS 66.0点(SD 21.1点);平均差异–0.65点,95%置信区间(CI)–3.98至2.68点;标准化效果大小–0.04,95%CI –0.23至0.15}。生活质量,踝关节运动,疼痛,活动能力和患者满意度没有差异。 ORIF感染和/或伤口问题较为普遍[29/298(10%)vs. 4/275(1%)],以及其他手术室手术程序[17/298(6%)vs. 3/275( 1%)]。 CCC中的Malunion更常见[38/249(15%)比8/274(3%); p <0.001]。在ORIF组中,踝骨不愈合率较低[侧面:0/274(0%)对8/248(3%); p = 0.002;内侧:3/274(1%)对18/248(7%); p <0.001]。在试验期间,CCC显示出中等程度的平均成本节省[NHS平均差– 644英镑(95%CI – 1390到76英镑);社会平均差异– 683英镑(95%CI – 1851英镑至536英镑)]。估计显示有些不精确。 CCC后的增量质量调整生命年与ORIF并无不同。在通常的支付意愿阈值之上,CCC具有成本效益的可能性非常高(从NHS角度来看> 95%,从社会角度来看则> 85%)。治疗经验相似。两组患者都承受了骨折的影响,未来功能的不确定性以及是否需要进一步的干预措施。 ud ud局限性: ud ud6周评估者未必盲目。 ud ud结论: ud udCCC可以在6个月内为NHS和整个社会降低成本,从而为ORIF提供临床等效的结果,从而降低了学习效果。 ud ud正在对试验参与者进行更长期的随访,以解决对以后可能出现的并发症或其他手术及其可能影响脚踝功能的担忧。进一步研究患者因素,放射性骨折类型和结局,治疗反应和预后也将有助于理解治疗途径。 ud ud试验注册: ud ud当前对照试验ISRCTN04180738。 ud ud资助: ud ud卫生研究所卫生技术评估计划,并将在《卫生技术评估》中全文发表;卷20,第75号。有关更多项目信息,请参见NIHR Journals Library网站。本报告是与美国牛津大学生物医学研究所的国家健康研究所资助计划一起制定的。试点阶段由AO研究基金会资助。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号